We have found that the JMJD6 gene is associated with transcriptional super-enhancers in JMJD6 gene-gained neuroblastoma cells, and that treatment with the CDK7 inhibitor THZ1, which specifically targets super-enhancer associated oncogenes12–14, significantly reduces JMJD6, N-Myc, and c-Myc expression. This evidence concerns the gene CDK7 and neuroblastoma.